Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04125732 · ClinicalTrials.gov registry record · Phase 1
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
A Phase 1 study, sponsored by XyloCor Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04125732 is a Phase 1 study that has completed, run by XyloCor Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT04125732, a Phase 1 study, has completed, sponsored by XyloCor Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).
Interventions
- BIOLOGICAL AdVEGFXC1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-01-24 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04125732
The ClinicalTrials.gov registry entry for NCT04125732 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XyloCor Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AdVEGFXC1 is the first listed.
NCT04125732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04125732 about?
NCT04125732 is a clinical study titled "Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)". The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular end...
What is the current status of trial NCT04125732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2020-01-24. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT04125732?
The interventions under investigation include: AdVEGFXC1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04125732?
This trial is sponsored by XyloCor Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.